Multiple immune effector targets

The term Multiple immune effector targets refers to a therapeutic strategy or a broad classification of agents rather than a single molecular entity. This approach involves the simultaneous modulation of various components of the immune system—such as T cells, Natural Killer (NK) cells, and myeloid cells—to achieve a synergistic therapeutic effect against complex diseases like cancer or chronic infections (Nature Reviews Drug Discovery, 2020). It is most commonly associated with multi-specific antibodies (e.g., bispecific T-cell engagers) and combination therapies that target multiple immune checkpoints or signaling pathways to overcome tumor heterogeneity and immune suppression (Journal of Hematology & Oncology, 2021). By engaging multiple effectors, these therapies aim to provide a more robust and sustained immune response compared to single-target agents. However, the complexity of hitting multiple targets simultaneously increases the risk of systemic inflammatory responses, such as cytokine release syndrome, and presents significant challenges in managing off-target toxicities and therapeutic windows (Blood, 2019).

Other names

Multi-target immunotherapyImmune effector cell targetsCombinatorial immune targetsMulti-specific immune engagement

Simultaneous or sequential engagement of various immune system components, such as T cells, Natural Killer (NK) cells, and macrophages, to enhance the anti-tumor or anti-pathogen response and overcome immune evasion mechanisms.